|[November 01, 2013]
New Online Community Connects People Affected by Challenging Seizure Disorder
DEERFIELD, Ill. --(Business Wire)--
Lundbeck today announced the launch of LGS
Together, an online initiative for people impacted by epilepsy,
including those affected by Lennox-Gastaut syndrome (LGS). LGS Together
will help parents and family members share their personal experiences
and find strength for the journey of caring for someone with a
challenging seizure disorder like LGS. The LGS Together launch coincides
with Epilepsy Awareness Month in November and LGS Awareness Day on Nov.
LGS Together is a result of collaboration among people with LGS, their
families and friends, leading epilepsy and LGS patient organizations and
Lundbeck. The website, LGSTogether.com,
features stories, advice and knowledge from members of the community, as
well as resources and information parents can use in their daily lives.
On the LGS
Together Facebook page, parents and families can get regular updates
about the program, discover epilepsy community events and activities,
share personal experiences and encourage each other.
"As a mother whose daughter has experienced seizures associated with LGS
for most of her life, I know how difficult it can be to find answers and
support," said Jane Medlock, a member of Lundbeck's LGS Working Group
whose insights and input led to the creation of the site. "I'm happy to
be able to share my story and be part of a community where parents and
family members can find strength from other people who really understand
the ins and outs of caring for someone with challenging seizures."
Throughout the month of November, the LGS Together Facebook (News - Alert) page will
feature the "Find Your Strength" campaign, which provides opportunities
for people to describe how they find strength in their daily lives.
Weekly posts will include videos highlighting unique insights and
providing encouragement to the epilepsy community. For each visitor who
"Likes" the weekly featured post, Lundbeck will make a $1 donation to
the LGS Foundation and Epilepsy Foundation, up to $10,000 to each
"We know from our ongoing conversations with members of the epilepsy
community that parents truly appreciate hearing from other families who
understand epilepsy and LGS. We created LGS Together to help foster that
connection," said Jill Gattone, manager of epilepsy advocacy and patient
support at Lundbeck. "Parents can visit the website to get guidance from
others living with LGS and join the Facebook page to extend the
For more information, please visit www.lgstogether.com
About Lennox-Gastaut Syndrome (LGS)
LGS is a rare and severe form of epilepsy.1 The most common
features of LGS are multiple types of seizures, frequent seizures,
delays in mental and/or physical motor skills and an abnormal EEG or
brain wave pattern.1,2 LGS typically occurs between 2-8 years
of age,3 and 80 percent of children diagnosed with LGS will
continue having seizures into their adult years.3 The
prognosis of Lennox-Gastaut syndrome can greatly vary from person to
person.4 Complete recovery, with freedom of seizures and
normal development, is unusual for a child with LGS. There is no cure
for the disorder.4
About the Lennox-Gastaut Syndrome Foundation
LGS Foundation is a non-profit organization dedicated to providing
information about Lennox-Gastaut syndrome while raising funds for
research, services and support for individuals living with LGS and their
The LGS Foundation is based in New York City and provides services and
information to thousands of members across the world.
About the Epilepsy Foundation
The Epilepsy Foundation, a national nonprofit with affiliated
organizations throughout the United States, has led the fight against
epilepsy since 1968. The Foundation's mission is to stop seizures, find
cures and overcome the challenges created by epilepsy. For additional
information, please visit www.epilepsyfoundation.org.
About Lundbeck in the U.S.
A wholly owned subsidiary of H. Lundbeck A/S in Denmark, Lundbeck U.S.
is headquartered in Deerfield, Illinois, and is committed to providing
innovative specialty therapies that fulfill unmet medical needs of
people with brain disorders. In its late-stage research pipeline, the
company has neurology compounds under investigation for Alzheimer's
disease, stroke and epilepsy, in addition to therapies in development
for mental health disorders.
With a special commitment to the epilepsy community, Lundbeck makes a
scholarship available to help families attend the LGS Foundation's
Family & Professional Conference. Each year our employees actively
support and participate in hundreds of community-based initiatives,
including Studio E, an art therapy program Lundbeck makes
available with the Epilepsy Foundation. Learn more about our epilepsy
community programs at YourPartnerInEpilepsy.com.
Lundbeck is a global pharmaceutical company highly committed to
improving the quality of life of people living with brain diseases. For
this purpose, Lundbeck is engaged in the entire value chain throughout
research, development, production, marketing and sales of
pharmaceuticals across the world. The company's products are targeted at
disorders such as depression and anxiety, psychotic disorders, epilepsy,
Huntington's, Alzheimer's and Parkinson's diseases. Lundbeck's pipeline
consists of several mid- to late-stage development programs.
Lundbeck employs more than 5,800 people worldwide, 2,000 of whom are
based in Denmark. We have employees in 57 countries and our products are
registered in more than 100 countries. We have research centers in
Denmark, China and the United States and production facilities in Italy,
France, Mexico, China and Denmark. Lundbeck generated revenue of
approximately DKK 15 billion in 2012. Lundbeck's shares are listed on
the stock exchange in Copenhagen under the symbol "LUN." Lundbeck has a
sponsored Level 1 ADR programme listed in the US (OTC) under the symbol
For additional information, we encourage you to visit our corporate site www.lundbeck.com.
1 Medscape. Lennox-Gastaut Syndrome. http://emedicine.medscape.com/article/1176735-overview.
2 Arzimanoglou, Alexis et al. Lennox-Gastaut syndrome: a consensus
approach on diagnosis, assessment, management, and trial methodology.
The Lancet. 2009: 8(1) 82-93.
3 Van Rijckevorsel, Kenou et al. Treatment of Lennox-Gastaut syndrome:
overview and recent findings. Neuropsychiatric Disease and Treatment.
2008: 4(6) 1001-1019.
4 NINDS. Lennox-Gastaut Syndrome Information Page. http://www.ninds.nih.gov/disorders/lennoxgastautsyndrome/lennoxgastautsyndrome.htm.
[ Back To Technology News's Homepage ]